Sana Biotechnology (NASDAQ:SANA) Price Target Lowered to $9.00 at HC Wainwright

Sana Biotechnology (NASDAQ:SANA) had its price objective dropped by analysts at HC Wainwright from $11.00 to $9.00 in a report released on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 132.86% from the company’s previous close.

Several other research analysts also recently weighed in on SANA. Citigroup reissued an “outperform” rating on shares of Sana Biotechnology in a research report on Thursday, October 30th. Citizens Jmp increased their target price on Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a report on Thursday, October 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 8th. JMP Securities set a $8.00 price objective on Sana Biotechnology in a research report on Thursday, October 30th. Finally, Wedbush initiated coverage on Sana Biotechnology in a report on Wednesday, September 24th. They issued an “outperform” rating and a $5.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.17.

Sana Biotechnology Trading Down 4.6%

NASDAQ:SANA traded down $0.19 during mid-day trading on Friday, reaching $3.87. 1,049,825 shares of the stock were exchanged, compared to its average volume of 5,679,035. Sana Biotechnology has a 1-year low of $1.26 and a 1-year high of $7.30. The firm has a market capitalization of $919.14 million, a PE ratio of -3.65 and a beta of 1.94. The business has a fifty day moving average price of $4.04 and a 200 day moving average price of $3.33.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.03. On average, sell-side analysts forecast that Sana Biotechnology will post -1.16 earnings per share for the current year.

Institutional Investors Weigh In On Sana Biotechnology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its position in shares of Sana Biotechnology by 180.8% in the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after purchasing an additional 1,375,029 shares during the period. WJ Financial Advisors LLC acquired a new position in Sana Biotechnology in the 3rd quarter valued at $43,000. Lyell Wealth Management LP bought a new position in Sana Biotechnology in the 3rd quarter worth $37,000. Profund Advisors LLC acquired a new position in Sana Biotechnology during the 3rd quarter worth $205,000. Finally, Savant Capital LLC boosted its holdings in Sana Biotechnology by 5.6% during the third quarter. Savant Capital LLC now owns 66,414 shares of the company’s stock valued at $236,000 after acquiring an additional 3,500 shares during the period. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.